TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Pulsatile IV Insulin on Circulating Risk Markers of Vascular and Metabolic Complications in Pts With Diabetes

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* We will include up to 500 patients both male and female over the age of 21 diagnosed with type 1 or type 2 diabetes mellitus~* All patients must have secondary complications caused by the diabetes and not responding to conventional medical management~* Under an Endocrinologists supervision for their diabetes management~* Endocrinologist must assess and approve patient for participation in this study~* Ability to swallow without difficulty~* Ability to commit to the weekly time requirements associated with the study~Exclusion Criteria:~* Other causes of complications not related to diabetes~* Lack of intravenous access~* Pregnancy~* Alcohol abuse, drug addiction or the use of illegal drugs~* Positive HIV~* Inability to perform breathe into machine for respiratory quotients

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 2 (Type: ACTIVE_COMPARATOR): Diabetic patients who meet inclusion criteria will be enrolled to start Pulsatile Intravenous Insulin Therapy on a weekly basis. Baseline testing will be performed and measured against continued testing every twelve months.
- 1 (Type: PLACEBO_COMPARATOR): Circulating blood markers will be performed on diabetic control patients at baseline and every twelve months to compare and measure against patients treated with Pulsatile intravenous insulin therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Concomitant Epicardial Pulmonary Vein Isolation in Patients With Atrial Fibrillation Undergoing Elective Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥ 18 years of age~* EHRA class ≤ 2~* Documented history of paroxysmal, persistent, longstanding persistent or newly-diagnosed AF prior to admittance for cardiac surgery~* Patients will have elective coronary surgery planned Able of providing informed consent~Exclusion Criteria:~* Patients ≥70 years of age~* Pregnancy Patients with contraindications for oral anticoagulant agents~* Patients undergoing emergency operation~* Patients undergoing concomitant valve replacement~* Severely enlarged LA (\>50 mm) on echocardiography~* Prior AF ablation or AF surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Usual care (Type: ACTIVE_COMPARATOR): None
- Pulmonary vein isolation (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Predicting Cell Death by Radiation Therapy in Early Stage Non-small Cell Lung Cancer: a Prospective Translational Trial

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Proof of cT1a/b - 2a/b N0M0 NSCLC~* Informed Consent signed~* Resectable tumour~* Operable patient~* \> 18 years old~* men and women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Varicocelectomy: Can Sex-hormones Predict Improvements in Semen Quality?

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Varicocele (grade 1-3) and surgery planned for this condition~* At least 18 years of age~Exclusion Criteria:~* Fever within 3 months before the first semen sample~* Malformations of the uro-genital tract~* Karyotype other than 46, XY or Y micro deletions~* Endocrine disease~* Chronic disease~* Medications which reduce semen quality~* Epididymitis within 6 months before surgery

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hormone/semen measurements before and after varicocelectomy (Type: EXPERIMENTAL): We will measure sex-hormone and semen quality in patients both before and after varicocelectomy. The purpose is to asses if preoperative hormone levels are predictive for who will have improved semen quality after surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Weighted Blankets After Brain Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Subjects capable of giving informed consent, or if appropriate, subjects having an acceptable individual capable of giving assent on the subject's behalf~* Aged over 18 years~* Admitted to King's Lodge Neurorehabilitation Unit for inpatient rehabilitation after a brain injury~* Within weight limits to be suitable for weighted blanket use~Exclusion Criteria~* On end of life pathway~* Pain which could be exacerbated by weighted blanket~* Unable to remove~* Presence of open wound / pressure sore~* Allergy to blanket material~* Participant or consultee unable or unwilling to give informed consent / assent~* Known respiratory disorder such as asthma, chronic obstructive pulmonary disease, obstructive sleep apnoea which could be exacerbated by use of heavy blanket over chest~* Claustrophobia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Weighted blankets (Type: EXPERIMENTAL): Provided with weighted blanket suitable for participant's weight
- Standard linen (Type: NO_INTERVENTION): Use of standard hospital linen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Quality of Life in Pediatric Transplant Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* between newborn and 21 years old~* parent/child pairs of patients listed for or who have received a liver transplant, kidney transplant, or heart transplant~Exclusion Criteria:~* unwilling or unable to participate~* not in one of the above transplant groups~* non-English speaking

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- QOL### (Type: None): All child subjects in this cohort will be listed for or already have received a solid organ transplant (kidney, heart, or liver).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Signals Electrophysiological Measured by Intelligent Textiles

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* women or men \>18 years~* affiliation to a social security system~Exclusion Criteria:~* Wounds or wounds on the body and the scalp;~* Refusal of consent, minor~* Not membership to the Social Security~* Participant not capable of following the procedure of use (according to the judgment of the investigator);~* Brain surgery that took place less than a week ago~* Allergy known about the money, the polyamide, the silicone, the synthetic materials;~* Sensory Disorders(Confusions) returning the insensible subject to the pain;~* Motor or mental disorders preventing the subject from expressing his pain;~* Behavioral problems that make the subject excessively agitated or aggressive;~* People with cardio-respiratory problems likely to be aggravated by the slight compression of the thorax;~* Subject equipped with an electrical stimulation device;~* Unsuitable anthropometric Parameters (for the women, the sizes superior to 24 will be excluded and for the men(people) those superior to 34);~* Pregnancy clinically detectable or known for the subject;~* Current(in class) Participation in a clinical trial or participation in a previous clinical trial understanding(including) a period of not past(over) deficiency at the time of this clinical trial.~* Predisposition in the headaches of tension (the compression exercised by the hat(cap) can activate(start) in certain cases a headache);~* Use of the device(plan) within the framework of a resuscitation or of intensive care;~* Participating carrier of a defibrillator, a stimulating of the vagus nerve, or quite different surgical high-frequency device.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- test of sensors for somnonaute device (Type: EXPERIMENTAL): monitoring with sensors
- test of sensors for uronaute device (Type: EXPERIMENTAL): monitoring with sensors
- test of sensors for toconaute device (Type: EXPERIMENTAL): monitoring with sensors
- test of sensors for cardioskin device (Type: EXPERIMENTAL): monitoring with sensors
- test of sensors for neuronaute device (Type: EXPERIMENTAL): monitoring with sensors

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of PMF, PPV MF or PET-MF, irrespective of JAK2 mutational status according to the 2008 revised International Standard Criteria~* Peripheral blast count \< 10%~* Requires therapy for MF in the opinion of the investigator~* Received prior monotherapy treatment with ruxolitinib for at least 12 consecutive weeks and experienced treatment interruption because of lossof response or adverse event~* Patients adhering to the Screening phase assessments and undergoing a a ruxolitinib-free washout period of a minimum of 1 week and a maximum of 8 weeks~* ECOG performance status 0, 1, 2, or 3~* Adequate bone marrow function~* Written informed consent~Exclusion Criteria:~* Patients not initially responding (primary resistance) to ruxolitinib therapy~* Patients who underwent a splenectomy or spleen radiation~* Patients currently scheduled for bone marrow transplant~* Patients who have discontinued ruxolitinib \< 14 days prior to screening~* Patients who are not able to receive a starting dose of ruxolitinib of at least 15 mg total daily dose~* Leukemic transformation~* Inadequate renal function~* Presence of clinically meaningful active bacterial, fungal, parasitic or viral infection which requires therapy~* Previous history of Progressive Multifocal Leuko-encephalopathy (PML)~* Clinically significant cardiac disease or significant concurrent medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib (Type: EXPERIMENTAL): All participants received ruxolitinib.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who have a diagnosis of Giant Cell Arteritis (GCA)~* Patients who have a diagnosis of GCA of = 4 weeks' duration~* Patients who are receiving = 40 mg/day of prednisone/prednisolone Exclusion Criteria:~* Patients must not have a prior diagnosis of GCA \> 4 weeks~* Patients must not have failed to respond to glucocorticosteroid therapy within 5 days of initiation of therapy.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the prostate with clinical or radiologic evidence of metastatic disease.~* Disease progression during antiandrogen therapy, having surgical or medical castration status.~* Karnofsky Performance Status 50-100~* Normal cardiac function~* Life expectancy at least 24 weeks.~* Laboratory criteria for eligibility will include~* A neutrophil count of at least 1500 per cubic millimeter~* A hemoglobin level of at least 9 gm%~* A platelet count of at least 1000,000 per cubic millimeter.~* A total bilirubin not grater than 1.5 times the upper limit of the normal range for each institution.~* Serum creatinine levels not more than 1.5 times the upper limit of the normal range~* Written informed consent~Exclusion Criteria:~* Prior treatment with cytotoxic agents or radioisotopes~* Estrogen use for at least three months~* History of another cancer within the preceding five years (except basal or squamous-cell skin cancer)~* Brain or leptomeningeal metastases~* Symptomatic peripheral neuropathy of grade 2 or higher~* Uncontrolled intercurrent illness that would limit compliance with study requirements

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2 (Type: EXPERIMENTAL): Docetaxel+Mw
- 1 (Type: ACTIVE_COMPARATOR): Docetaxel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Detection of Choroidal Nevus Cells in Vitrectomy Fluid

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with a choroidal nevus who are undergoing routine vitrectomy surgery for another indication (such as epiretinal membrane or macular hole repair).~Exclusion Criteria:~* Patients without a choroidal nevus~* Children under the age of 18~* Pregnant and nursing females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Quick Start Initiation of the Contraceptive Vaginal Ring in Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: 1) female aged 15 through 21 presenting for contraception; 2) willing to use the NuvaRing as their contraceptive method; 3) English-speaking; 4) up to date on routine health maintenance screening (pap smear within 3 years of initiation of sexual intercourse and Gonorrhea/ Chlamydia testing yearly or with each new partner); and 5) able to read and understand the consent form.~Exclusion Criteria: 1) are pregnant; 2) have a contraindication to hormonal contraception; 3) are unwilling to use NuvaRing as their contraceptive method; 4) are currently using any hormonal contraceptive or have used one within past 2 months; 5) have used emergency contraception in the past 7 days; 6) have had unprotected intercourse in the past 10 days; 7) have untreated Gonorrhea or Chlamydia; or 8) are unable to give informed consent because of psychiatric or cognitive problems.

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 21 Years
- Healthy Volunteers: t

Study Arms:
- Quick start (Type: EXPERIMENTAL): Start contraceptive method (NuvaRing) day of enrollment
- Traditional start (Type: ACTIVE_COMPARATOR): Start contraceptive method (NuvaRing) after next menses (per package insert)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Coagulation and Fibrinolysis of Estradiol in Transwomen

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* Gender identity of male to female or transwoman~Exclusion Criteria:~* Liver disease~* History of blood clot~* Bleeding disorder~* Active or recent (e.g., within the past year) stroke~* Myocardial infarction,~* History of orchiectomy~* History of breast cancer,~* Known sensitivity or allergy to any components of the medications used~* Currently taking a potent CYP3A4 inhibitor or inducer.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Sublingual Estradiol (Type: ACTIVE_COMPARATOR): Sublingual estradiol administered for 8 weeks
- Oral Estradiol (Type: ACTIVE_COMPARATOR): Oral estradiol administered for 8 weeks
- Transdermal Estradiol (Type: ACTIVE_COMPARATOR): Transdermal estradiol administered for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Identify and Characterise Bacteria Causing Chronic Cough Among Children in United Kingdom

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that parent(s)/ legally acceptable representative can and will comply with the requirements of the protocol.~* A male or female child between, and including, six to 72 months of age at the time of enrolment.~* Written informed consent obtained from the parent(s)/ legally acceptable representative of the subject.~* No antibiotic therapy within four weeks prior to the visit.~* No cystic fibrosis or known major immunodeficiency such as agammaglobulinaemia, T cell deficiency or Human Immunodeficiency Virus / Acquired Immune Deficiency Syndrome.~* No documented evidence or suspicion of gastroesophageal reflux disease.~* No evidence of an upper viral respiratory infection four weeks prior to the visit.~In addition, all subjects regarded as 'cases' must satisfy all the following criteria at study entry:~* Persistent cough greater than eight weeks.~* No response to five-day prednisolone treatment.~* Chest X-ray showing no evidence of a lobar pneumonia or gross structural abnormality.~In addition, all subjects regarded as 'controls' must satisfy the following criteria at study entry:~* No respiratory symptoms four weeks prior to the visit.~* No documented evidence or suspicion of lung disease upon physical examination.~Exclusion Criteria:~* Concurrently participating in another study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.~* Use of any investigational or non-registered product within 30 days prior to study procedures, or planned use during the study period.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* Child in care.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 72 Months
- Healthy Volunteers: f

Study Arms:
- Cases (Type: None): Subjects diagnosed with chronic cough who are undergoing general anaesthesia and bronchoscopy/BAL as part of the diagnostic process for chronic cough.
- Controls (Type: None): Subjects without respiratory symptoms who are undergoing general anaesthesia for elective surgery or endoscopy of non-respiratory-related conditions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues